Unicycive Therapeutics Files 8-K Report

TL;DR

Unicycive Therapeutics filed an 8-K on Jan 7, 2025 - details TBD.

AI Summary

On January 7, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Los Altos, California.

Why It Matters

This filing signals a material event for Unicycive Therapeutics, Inc., requiring disclosure to investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report of an 'Other Event' without immediate disclosed financial or operational impact.

Key Players & Entities

• Unicycive Therapeutics, Inc. (company) — Registrant
• January 7, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Los Altos, CA (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $1.00 — ness days, had closed below the minimum $1.00 per share and, as a result, the Company
• $1.00 m — Company was not in compliance with the $1.00 minimum bid price requirement for the con

Filing Documents

• ea0227071-8k_unicycive.htm (8-K) — 32KB
• 0001213900-25-001640.txt ( ) — 203KB
• uncy-20250107.xsd (EX-101.SCH) — 3KB
• uncy-20250107_lab.xml (EX-101.LAB) — 33KB
• uncy-20250107_pre.xml (EX-101.PRE) — 22KB
• ea0227071-8k_unicycive_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction (Commission File Number) IRS Employer of incorporation or organization) Identification No.) 4300 El Camino Real , Suite 210 Los Alto , CA 94022 (Address of principal executive offices) Registrant's telephone number, including area code: ( 650 ) 351-4495 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock UNCY Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On July 9, 2024, Unicycive Therapeutics, Inc. (the "Company") received written notice (the " Notice ") from the Nasdaq Stock Market, LLC (" Nasdaq ") indicating that the bid price for the Company's common stock (the "Common Stock"), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company was not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company had a period of 180 calendar days, or until January 6, 2025, to regain compliance with the minimum bid price requirement. As of January 6, 2025, the Company has not regained compliance with the minimum bid price requirement. On January 7, 2025, Nasdaq notified the Company that it would have an additional 180 calendar days, or until July 7, 2025, to regain compliance. The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price under the Nasdaq Listing Rules. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 7, 2025 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR